Canaccord initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $39 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics to expand Phase 3 SELVA trial to include younger patients
- Palvella Therapeutics initiated with a Buy at TD Cowen
- Promising Potential of Palvella Therapeutics’ QTORIN Platform Drives Buy Rating
- Four new option listings and one option delisting on January 29th
- Palvella Therapeutics announces results from Phase 2 study of QTORIN